Federal Court rules in favour of Janssen in patent dispute over schizophrenia drug
The Federal Court has found that a Montreal pharmaceutical company would be infringing on another company’s patent for a drug used to treat schizophrenia should it market its own generic version....To view the full article, register now.
Already a subscriber? Click here to view full article